AIFA Agenzia Italiana del Farmaco
Web activation and publication of monitoring cards — Registro — Opdivo (RCC)
Users of the Drug Registries subject to Monitoring are informed that, following the publication of the AIFA Determine in the OJ no. 256 of , starting from it is possible to use, under the NHS reimbursement scheme, medicinal products (cabozantinib) and OPDIVO (nivolumab) for the following therapeutic indication:
, in combination with OPDIVO, is indicated for the first-line treatment of advanced renal cell carcinoma in adult patients.
Please note that the prescriptions relating only to the indication reimbursed by the National Health Service, through the aforementioned publication, must be carried out in accordance with the criteria of eligibility and prescriptive appropriateness reported in the clinical card, downloadable from the list of «Active Registers and PT», accessible from the «Related Links» box.
Finally, it is specified that, starting from , the register in question is available on the web platform; therefore the regional referents are invited to proceed with the authorization of authorized health centers, accessing the system.
Monitoring Registers Office
Published on:
— Reproduction reserved and for personal use
— Download the complete document in PDF format from the link at the bottom of the page
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum number of visits
Source — https://www.univadis.it/viewarticle/attivazione-web-e-pubblicazione-schede-di-monitoraggio—registro-cabometyx—opdivo-rcc